Speech-Language Pathologists in Franklin, OH Accepting Medicare

4 Speech-Language Pathologists found. Showing 1 - 4

Katherine Dimario Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4418 State Route 122, Franklin, OH 45005 Phone: 937-743-8655

Magan Mcclurg, MA., CF- SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 750 E 4th St, Franklin, OH 45005 Phone: --

Carolyn Tonnis, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 150 E 6th St, Franklin, OH 45005 Phone: 937-743-5290

Cynthia Banks, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 150 E 6th St, Franklin, OH 45005 Phone: 937-743-8602

News Archive

Conference highlights new biological advances in diagnosis and prognosis of lung cancer

Promising results from Phase II clinical trials and important biological advances in diagnosis and prognosis will be presented here, at the conference on Molecular Origins of Lung Cancer from Jan. 11-14, 2010. This conference is jointly sponsored by the AACR and the International Association for the Study of Lung Cancer.

Lung function decline and outcomes in an adult population

Rapid lung function decline significantly increases the risk of death and hospitalization for individuals with chronic obstructive pulmonary disease (COPD).

Triage NGAL bedside blood test helps identify AKI risk: New study

According to a new study published last week in Intensive Care Medicine, a novel bedside blood test measured in critically ill patients being admitted to the intensive care unit can help to identify which patients are at risk for acute kidney injury (AKI). The study carried out in Vicenza, Italy, tested blood samples collected during admission to the ICU using the Triage® NGAL Test, a product currently sold by Inverness Medical Innovations, Inc. outside of the United States.

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).

International community should unite to ensure adequate family planning services for women in West Africa, globally

"For many years, in large parts of West Africa, the percentage of women who use contraception has stalled at less than 10 percent, leading many to declare that there is very little or no demand for family planning (FP) in the region.

Read more Medical News

› Verified 2 days ago